We found that the frequencies of circulating CD3+ T cells did not differ across healthy donors or those with either localized or metastatic disease, but the percentage of composition of peripheral CD19+ B cells was lower among patients with metastatic disease compared with healthy controls (Figure 5, A and B). This evidence concerns the gene CD19 and metastatic neoplasm.